Today I want to give you two of the best investments in energy security – one of the most important new opportunities in the oil and gas sector.
Energy security stems from the accelerating need to protect the production, transport, and distribution of our newfound wealth in oil and gas.
Now energy security is growing into a handsome profit opportunity of its own...
by Robert Hsu
Each January, we hear a chorus of pundits making predictions about where the markets will go in the 12 months ahead. The number and volume level of the "predictions" is matched only by the utter lack of evidence to back them up.
These talking heads will be the first to shout "I told you so!" But when they get it wrong, well… the silence is deafening. Their predictions are of little use to us.
But predictions themselves can be very useful. Making a well-reasoned prediction can be a great way to crystallize your thinking on important issues. It's also a good filter that can help you select which trends and sectors to embrace – and which to avoid – over the year ahead.
by Diane Alter
Making the right penny stock picks can score investors triple-digit gains in a matter of weeks – or days.
Chelsea Therapeutics International Ltd (Nasdaq: CHTP) gained as much as 120% Jan. 15 when it got drug approval from an FDA advisory panel. That brings the drug one step closer to FDA approval.
To continue reading, please click here...
Golar LNG stock is not the typical way to invest in the coming liquefied natural gas (LNG) export industry – but it will be one of the most profitable.
You see, while the global economy's struggles have hurt shipping stocks over the past few years, the shipping subsector of LNG carriers is currently flourishing, with about 10% annual growth over the last decade. LNG carriers transport natural gas that's been cooled to minus 260 degrees Fahrenheit.
it's going to be one of the most profitable...
Stock Market News Today, Jan. 17: The Dow is up but the S&P 500 and Nasdaq down in afternoon trading, and here's why…
Housing market data today revealed that new home construction fell 9.8% in December to a seasonally adjusted rate of 999,000. The numbers were weighed by starts for single-family homes and apartments, the U.S. Commerce Department reported.
To continue reading, please click here...
by David Zeiler
The recent data breach at Target is one of the worst breaches of credit card information ever. But if those millions of Target Corp. (NYSE: TGT) customers had been using Bitcoin instead of credit cards, the thieves could not have stolen any of their personal data.
The thieves who stole the credit card data from Target customers took the information from Target's own computer systems. They got credit card numbers, names, and home addresses. In short order, the Target thieves were selling this data to other criminals over the Internet.
Here's why Bitcoin is destined to replace credit cards...
General Electric Co. (NYSE: GE) will report earnings Friday morning, and analysts are projecting earnings per share of $0.53 on revenue of $40.2 billion.
The $0.53 EPS estimate is a 20% increase from General Electric's 2012 Q4 earnings. Likewise, the revenue estimate is 2% higher than the $39.3 billion revenue GE reported in the previous year.
To continue reading, please click here...
Editor's Note: Today, we'd like to welcome Ernie Tremblay to Money Morning. He's been providing his bioscience research to our premium services for over a year now and we couldn't be more thrilled with the results, including a 457% gain on one of his recommendations. So here's how Ernie does it…
Traditional pharmaceutical blockbusters like Pfizer's Lipitor treat millions of patients at relatively low cost. It's a high-volume business model that has kept the pharmaceutical industry afloat for a long, long time. But over the past decade, out of necessity, a new model has taken the industry by storm.
As big moneymakers, like Lipitor, reach the "patent cliff," their intellectual rights protection are evaporating, and generic drug makers are taking over their markets.
Big Pharma needs fresh drugs to take the place of those they're losing. But replacing these products with new ones is expensive. Most experts agree that it takes about $800M in capitalized costs to develop a single new drug. And frankly, the "easier" medical riddles, like treating high LDL cholesterol, have mostly been solved. The remaining tough ones, like cancer and Alzheimer's, will drive costs even higher.
So how do the major pharmaceutical companies meet the challenge? By letting small, smart start-up biotechs do the R&D legwork on new drugs, then either making distribution deals with them or buying the small companies out.
Here's what makes this new approach so lucrative for investors...
The U.S. Treasury Department said today (Thursday) that total foreign holdings of U.S. debt rose 1.1% in November to $5.72 trillion, putting foreign holdings 0.1% below the all-time high of $5.76 trillion it reached in March 2013.
In particular, China's holdings reached record levels, increasing 0.9% to $1.32 billion, and so did Japan, which boosted its holdings by 1% to $1.19 trillion. The two countries are the largest and second-largest foreign buyers of Treasury debt, respectively.
To watch the video, click here...
